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ABSTRACT
Objectives  To compare the risk of keratinoctye skin 
cancer (basal cell carcinoma (BCC) and squamous cell 
carcinoma (SCC)) in patients treated for rheumatoid 
arthritis (RA) compared with the general population, and 
to determine whether anti-tumour necrosis factor (TNF) 
therapy exacerbates this risk.
Methods  Patients with RA enrolled in the British Society 
for Rheumatology Biologics Register, a prospective 
national cohort established in 2001 to monitor the safety 
of anti-TNF, were followed until 2008. 11 881 patients 
treated with anti-TNF were compared with 3629 patients 
receiving non-biological disease-modifying antirheumatic 
drugs (nbDMARD). Standardised incidence ratios (SIR) 
were calculated for each cohort and rates between 
cohorts were compared using Cox proportional HR, 
adjusted using inverse probability of treatment weighting.
Results  SIR for skin cancer was increased in both 
cohorts compared with the English population: SIR 1.72 
(95% CI 1.43 to 2.04) anti-TNF; 1.83 (95% CI 1.30 to 
2.50) nbDMARD only. In patients without previous skin 
cancer, BCC incidence per 100 000 patient-years was 342 
(95% CI 290 to 402) after anti-TNF and 407 (95% CI 288 
to 558) after nbDMARD. HR after anti-TNF adjusted for 
treatment weighting was 0.95 (95% CI 0.53 to 1.71). SCC 
incidence per 100 000 patient-years: anti-TNF 53 (95% CI 
33 to 79); nbDMARD 43 (95% CI 12 to 110); adjusted HR 
1.16 (95% CI 0.35 to 3.84).
Conclusions  Skin cancers were increased among 
treated patients with RA. No evidence was found that 
anti-TNF therapy exacerbates the risk of BCC or SCC but 
this cannot be excluded. Patients with RA should use sun 
protection and be monitored for skin cancer.
Keratinocytic skin cancers, referred to here as ‘skin 
cancer’, mostly comprise basal cell carcinoma (BCC) 
(approximately 75%)1 and squamous cell carcinoma 
(SCC). These are the most commonly diagnosed 
cancers in the USA and UK.2 3 The annual inci-
dence of skin cancer varies by latitude, age and sex. 
In New Hampshire, USA (1993–4) the age-adjusted 
rates per 100 000 population for BCC were 310 in 
men and 166 in women,4 whereas in Arizona, USA 
(1996), corresponding rates for BCC were 936 and 
497 in men and women, respectively.5
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Some studies have found an increased risk of 
skin cancer in patients treated for rheumatoid 
arthritis (RA),6 7 whereas other studies have not.8 9 
A Swedish study found no increased risk of SCC 
in a cohort of patients with early RA but did ﬁ  nd a 
66% increased risk in patients with prevalent RA.10 
The standardised incidence ratio (SIR) for SCC 
increased with the duration of follow-up, suggest-
ing the risk may be related to cumulative RA dura-
tion and/or immunosuppressive therapy.
Anti-tumour necrosis factor (TNF) drugs have 
proved highly successful in treating RA. Five anti-
TNF drugs are approved for use in North America 
and Europe; etanercept, adalimumab, inﬂ  iximab, 
golimumab and certolizumab pegol. The introduc-
tion of TNF inhibitors has been accompanied by 
concerns regarding safety, and in particular the risk 
of malignancy.11 As the most common malignancies 
are skin cancers, then if TNF inhibition does have 
an effect on the risk of malignancy, one might pre-
dict that the signal would be seen ﬁ  rst in the skin. 
Data from clinical trials and observational studies 
in North America and Sweden have reported an 
increased risk of skin cancer with anti-TNF com-
pared with the general population and untreated 
patients with RA.10 12–14
The ﬁ  rst aim of this study was to compare the 
incidence of skin cancer in anti-TNF-exposed and 
biological-naive patients with rates in the UK gen-
eral population, using data from a national UK 
cohort of people with RA. The second aim was to 
explore the additional inﬂ  uence, if any, of anti-TNF 
therapy on the incidence of BCC and SCC by com-
paring incidence rates in these two cohorts.
METHODS
Patients
The subjects’ written consent was obtained. 
The study was approved by the North-West 
Multicentre Research Ethics Committee. Subjects 
were participants in the British Society for 
Rheumatology Biologics Register (BSRBR), a 
national prospective observational study estab-
lished in 2001 to monitor the long-term safety of 
biological therapy in RA. UK national guidelines 
recommend that anti-TNF is restricted to patients 
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and JBG) independently veriﬁ  ed all reports of skin cancers. Skin 
cancers were veriﬁ  ed if they were reported by NHS–IC or histol-
ogy conﬁ  rmed the diagnosis. Bowen’s disease and known pre-
existing skin cancers were excluded.
Statistical analysis
The risk of skin cancer in RA patients living in England was 
compared with the English general population. Age and gender-
standardised rates of skin cancer for the entire UK population 
were not available and numbers of skin cancers occurring in 
BSRBR patients living in Northern Ireland, Scotland and Wales 
were insufﬁ  cient for individual analyses. For England, SIR were 
calculated separately for the nbDMARD and anti-TNF cohorts. 
English population rates of skin cancer (excluding melanoma) 
from 2003 to 2008 were used. To ensure consistency between 
observed and expected rates we included only those cancers that 
with active disease (deﬁ  ned as 28 joint disease activity score 
(DAS28) >5.1) despite treatment with at least two non-bio-
logical disease-modifying antirheumatic drugs (nbDMARD), 
one of which should be methotrexate.15 These guidelines 
recommend against the use of anti-TNF in patients with ear-
lier malignancy within the previous decade. During the time 
period studied in this analysis, three anti-TNF agents were 
available in the UK: inﬂ  iximab, etanercept and adalimumab. 
A comparison cohort of biological-naive RA patients was 
recruited in parallel and followed in an identical manner to 
the anti-TNF cohort.16 These patients had active disease at 
recruitment (DAS28 ≥4.2) despite current treatment with at 
least one nbDMARD.
Patients were eligible if they had a physician diagnosis of 
RA and at least one returned rheumatologist follow-up ques-
tionnaire before 31 December 2008. The anti-TNF cohort was 
restricted to patients who received an anti-TNF as their ﬁ  rst 
biological therapy and who registered with the BSRBR within 
6 months of starting treatment. Patient-years of follow-up time 
were calculated from the date of starting an anti-TNF, or the 
date of registration with the BSRBR for the nbDMARD cohort. 
Follow-up was censored at the date of the most recently 
received hospital follow-up form before 31 December 2008 or 
death, if this came ﬁ  rst. Patients were not censored at the point 
of skin cancer diagnosis, as they could be diagnosed with more 
than one skin cancer during follow-up. While only cancers diag-
nosed before 31 December 2008 were included in the analy-
ses, we accepted all reports of such cancers up to 30 September 
2010, to allow for any lag in cancer reporting to the BSRBR. 
Patients in the nbDMARD cohort who subsequently started 
an anti-TNF contributed follow-up time up until the date of 
the ﬁ  rst dose of anti-TNF. As anti-TNF therapy may continue 
to inﬂ  uence the risk of skin cancer after its cessation, follow-
up time after stopping anti-TNF was included in the analysis. 
Patients were censored from the analysis at the point of starting 
a biological disease-modifying antirheumatic drug other than 
anti-TNF.
Baseline assessment
Baseline data included demographics, disease duration, disease 
activity, current and past nbDMARD, comorbidities and smok-
ing history. Patients completed a Stanford health assessment 
questionnaire (HAQ)17 to indicate their level of physical disabil-
ity. Previous malignancies, including skin cancers, were reported 
directly by the National Health Service Information Centre 
(NHS–IC) who link with the Ofﬁ  ce for National Statistics, which 
has been shown to register 90% of malignancies diagnosed in 
the UK accurately.18 Registration of skin cancer is less complete 
as the UK Association of Cancer Registries suggests that only 
the ﬁ  rst BCC or SCC per patient should be recorded.19
Follow-up
Changes to therapy were reported on rheumatologist question-
naires 6-monthly for 3 years, then annually thereafter. Data on 
adverse events were captured in three ways: from rheumatolo-
gist questionnaires; from 6-monthly patient diaries completed 
for 3 years; and by ﬂ  agging with NHS–IC, which reported 
malignancies using the 10th edition of the International 
Classiﬁ   cation of Diseases (ICD-10) and the International 
Classiﬁ  cation of Diseases for Oncology, which distinguishes 
between BCC and SCC.
Additional information (including histology) was sought from 
physicians for all incident skin cancers. Two physicians (LKM 
Figure 1  Flowchart showing selection of patients for the analysis. 
nbDMARD, non-biological disease-modifying antirheumatic drug; RA, 
rheumatoid arthritis; TNF, tumour necrosis factor.
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Individual comparisons of the anti-TNF agents with the nbD-
MARD cohort were made for BCC. A BCC was attributed to 
the anti-TNF prescribed at the time of skin cancer diagnosis, 
or to the most recently received anti-TNF. Three sensitivity 
analyses on the rate of BCC were planned in advance. First, an 
analysis was limited to the ﬁ  rst BCC per patient only. Second, 
to investigate the effects of any possible screening bias, the 
ﬁ  rst year of follow-up was excluded from the analysis. Third, 
an analysis was performed limited to patients with a previous 
history of reported BCC. No drug-speciﬁ  c analyses were per-
formed for SCC. As SCC are rare in the UK population aged 
had been reported to us from NHS–IC. Patients with a history 
of skin cancer before registration were included in this analysis 
because such patients could not be excluded from the popula-
tion rates.
Risk comparisons were made between the anti-TNF and 
nbDMARD cohorts, ﬁ  rst limited to patients without a previ-
ous history of skin cancer (BCC, SCC, melanoma or other skin 
cancer) at the time they joined the BSRBR. Rates of BCC and 
SCC are presented as total events per 100 000 patient-years 
with 95% CI. Survival analysis using Cox regression was used 
to compare the difference in risk between the anti-TNF and 
nbDMARD cohorts. Potential confounders were identiﬁ  ed a 
priori and comprised potential risk factors for skin cancer (age, 
sex, smoking and previous exposure to ciclosporin and aza-
thioprine), non-steroidal anti-inﬂ  ammatory drugs (NSAID), as 
these have been shown to protect against skin cancer,20 and 
differences in baseline characteristics (DAS28, HAQ, disease 
duration, baseline steroid use and year of entry to the study). 
Adjustment for these covariates was performed by calculating 
a propensity score, which reﬂ  ected the likelihood that an indi-
vidual patient was prescribed an anti-TNF given their known 
characteristics. The inverse of this score (or one minus the 
inverse for the nbDMARD cohort) was used as a weight in the 
Cox regression analysis. Missing baseline data were replaced 
using multiple imputations (see supplementary methods, 
available online only). The assumption of proportionality was 
tested using Schoenfeld residuals and met.
Table 1  Baseline characteristics of patients
  nbDMARD n=3629 All anti-TNF n=11 881
First anti-TNF drug
Etanercept n=4139 inﬂ  iximab n=3475 Adalimumab n=4267
Mean age, years (SD) 60 (12) 56 (12) 56 (12) 56 (12) 57 (12)
Women, % 2621 (72) 9053 (76) 3193 (77) 2626 (76) 3234 (76)
Country of residence (%)
  England 3066 (84) 10 064 (85) 3572 (86) 3039 (87) 3453 (81)
  Northern Ireland 365 (10) 299 (3) 45 (1) 56 (2) 198 (5)
  Scotland 156 (4) 920 (8) 287 (7) 188 (5) 445 (10)
  Wales 42 (1) 598 (5) 235 (6) 192 (6) 171 (4)
Smoking history, n (%)
  Current smoker 857 (24) 2580 (22) 846 (20) 757 (22) 977 (23)
  Former smoker 1437 (40) 4510 (38) 1576 (38) 1314 (38) 1620 (38)
  Never smoked 1317 (36) 4714 (40) 1691 (41) 1386 (40) 1637 (38)
  Not recorded 18 (0) 77 (1) 26 (1) 18 (1) 33 (1)
Ethnicity, n (%):
  White 2780 (77) 9829 (83) 3434 (83) 2814 (81) 3581 (84)
  Other 70 (2) 404 (3) 141 (3) 126 (4) 137 (3)
  Not recorded 779 (21) 1648 (14) 564 (14) 535 (15) 549 (13)
Skin cancer before registration, n (%) 106 (2.9) 177 (1.5) 68 (1.6) 40 (1.2) 69 (1.6)
Mean DAS28 (SD) 5.1 (1.3) 6.6 (1.0) 6.6 (1.0) 6.6 (1.0) 6.5 (1.0)
Mean HAQ (SD) 1.5 (0.8) 2.0 (0.6) 2.1 (0.6) 2.1 (0.5) 1.9 (0.6)
Median disease duration, years (IQR) 6 (1, 15) 11 (6, 19) 12 (6, 19) 12 (6, 19) 10 (5, 18)
Baseline steroid use, n (%) 831 (23) 5252 (44) 1979 (48) 1609 (46) 1664 (39)
Baseline NSAID use, n (%) 1964 (54) 6976 (59) 2439 (58) 2513 (59) 2513 (59)
Number of previous DMARD, median (IQR) 2 (1, 3) 4 (3, 5) 4 (3, 5) 4 (3, 5) 3 (3, 5)
Ever exposed to azathioprine, n (%) 259 (7) 2474 (21) 1059 (26) 719 (21) 696 (16)
Ever exposed to ciclosporin, n (%) 150 (4) 1943 (16) 792 (19) 704 (20) 447 (10)
Entry year
  pre-2003 8 (0) 1415 (12) 205 (5) 1180 (34) 30 (1)
  2003 309 (9) 311 (26) 1531 (37) 1106 (32) 479 (11)
  2004 891 (25) 3279 (28) 1978 (48) 506 (15) 795 (19)
  2005 925 (25) 1618 (14) 422 (10) 343 (10) 853 (20)
  2006 751 (21) 1137 (10) 2 (0) 275 (8) 860 (20)
  2007 337 (9) 842 (7) 1 (0) 65 (2) 776 (18)
 2008 408 (11) 474 (4) 0 (0) 0 (0) 474 (11)
DAS28, disease activity score in 28 joints; HAQ, health assessment questionnaire; nbDMARD, non-biological disease-modifying antirheumatic drug; NSAID, non-steroidal anti-inﬂ  ammatory 
drug; TNF, tumour necrosis factor.
Table 2  Standardised incidence ratios of NHS–IC reported skin 
cancers in England compared with England population 2003–8 (including 
patients with previous skin cancer)
Skin cancer (excluding melanoma) ICD-10 C44
  No Expected SIR (95% CI)
nbDMARD 39 21.34 1.83 (1.30 to 2.50)
Men 15 8.97 1.67 (0.94 to 2.76)
Women 24 12.38 1.94 (1.24 to 2.89)
Anti-TNF 126 73.44 1.72 (1.43 to 2.04)
Men 48 23.79 2.02 (1.49 to 2.68)
Women 78 49.65 1.57 (1.24 to 1.96)
ICD-10, International Classiﬁ  cation of Diseases, 10th edition; nbDMARD, non-biological 
disease-modifying antirheumatic drug; NHS–IC, National Health Service Information 
Centre; SIR, standardised incidence ratio; TNF, tumour necrosis factor.
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under 55 years,21 22 a sensitivity analysis for SCC restricted to 
patients aged over 55 years was performed. In addition to the 
main ‘ever exposed to anti-TNF’ analyses, rates of BCC and 
SCC in patients actively receiving anti-TNF, or within 90 days 
of stopping (‘on drug’), were compared with nbDMARD. All 
analyses were conducted using Stata version 10.1.
RESULTS
Three thousand six hundred and twenty-nine nbDMARD and 
11  881 anti-TNF patients were included (ﬁ   gure 1). The anti-
TNF cohort was younger and comprised more women (table 1). 
Eighty-ﬁ  ve per cent of patients were living in England. A known 
previous history of skin cancer was lower in the anti-TNF cohort 
(1.5% vs 2.9%). The anti-TNF cohort had more severe disease of 
longer duration. Two hundred and thirty-four patients enrolled 
in the nbDMARD cohort subsequently registered with the anti-
TNF cohort and so contributed follow-up time to both. Twenty-
four patients were censored from nbDMARD and 1327 from 
anti-TNF when starting other biological therapy.
Risk of skin cancer in patients with RA compared with the 
general population for England
The SIR for overall skin cancer was similar and signiﬁ  cantly 
increased in both treatment cohorts; SIR 1.72 (95% CI 1.43 
to 2.04) anti-TNF; 1.83 (95% CI 1.30 to 2.50) nbDMARD 
(table 2). In the anti-TNF cohort, the SIR was higher for men 
than women (2.02, 95% CI 1.49 to 2.68 vs 1.57, 95% CI 1.24 
to 1.96) whereas in the nbDMARD-only cohort the SIR was 
higher in women.
Risk of skin cancer for anti-TNF in patients without known past 
history of skin cancer
This analysis included 14 993 patients. One thousand nine hun-
dred and twenty-eight patients received more than one anti-TNF 
drug during follow-up. Two hundred and nineteen skin cancers 
were diagnosed during 53 140 patient-years of follow-up (176 
in the anti-TNF cohort and 43 in the nbDMARD cohort (tables 
3,4)). For anti-TNF, 19% of patients with incident skin cancer 
had multiple or recurrent lesions compared with 8% of the nbD-
MARD-only cohort (χ2 p=0.093). In the anti-TNF cohort, 121 
(87%) ﬁ  rst skin cancers were reported via NHS–IC compared 
with 36 (95%) in the nbDMARD cohort (χ2 p=0.185). One hun-
dred and twenty-four (70%) of the skin cancers in the anti-TNF 
cohort occurred while the patient was receiving an anti-TNF 
drug. All skin cancers occurred in white patients.
Basal cell carcinoma
The unadjusted risk of BCC for anti-TNF compared with nbD-
MARD only was 0.84 (95% CI 0.58 to 1.20; table 4). Age, male 
gender, disease duration and previous exposure to azathioprine 
or ciclosporin were associated with a risk of BCC in univari-
ate analysis (see supplementary table S1, available online only). 
Current smokers and patients taking NSAID at baseline were at 
reduced risk of BCC in univariate analysis. The fully adjusted 
HR for anti-TNF was 0.95 (95% CI 0.53 to 1.71). Analysis strati-
ﬁ  ed by anti-TNF drug found a higher risk for inﬂ  iximab than for 
the other two anti-TNF, although this was not statistically sig-
niﬁ  cant. The observed risk for inﬂ  iximab was further attenuated 
in a sensitivity analysis limited to ﬁ  rst BCC. After excluding the 
ﬁ  rst year of follow-up, the HR for anti-TNF was not signiﬁ  cantly 
increased (1.18, 95% CI 0.60 to 2.32).
Squamous cell carcinoma
The unadjusted HR for anti-TNF was 0.93 (95% CI 0.32 to 2.76; 
table 4). After adjustment for treatment weighting there was no 
association between anti-TNF and SCC (HR 1.16, 95% CI 0.35 
to 3.84). When restricted to patients aged over 55 years the HR 
for anti-TNF was 1.32 (95% CI 0.33 to 5.32).
Risk of BCC in patients with known previous skin cancer
Two hundred and eighty-three patients had a history of skin 
cancer before entering the study (177 anti-TNF cohort; 106 nbD-
MARD cohort). The crude incidence rate of BCC was 10-fold 
higher in this cohort compared with those without previous 
cancer, and higher in the nbDMARD cohort compared with 
anti-TNF (7982 per 100 000 patient-years vs 4623 per 100 000 
patient-years). The adjusted risk for anti-TNF was 0.70 (95% CI 
0.26 to 1.94).
DISCUSSION
The BSRBR is the largest biologicals register of its kind, with 
detailed follow-up for a median of 4 years and up to 8 years. 
The study has the unique advantage of the ﬂ  agging of patients 
with the NHS–IC that provided details of all registered previous 
and incident BCC and SCC. The results show that compared 
with the general English population, the overall risk of skin 
cancer was increased in patients treated for RA, regardless of 
treatment history.
Our ﬁ  ndings add to the results of several observational studies 
of RA.6–8 10 23–25 A Danish study found a 40% increased risk of 
SCC and 30% relative increase in BCC.7 However, this ﬁ  nding 
has not been consistent, and studies from Finland, Sweden and 
Table 3  Skin cancer reported in patients without previous history of skin cancer
  nbDMARD Anti-TNF Etanercept Inﬂ  iximab Adalimumab
Number ever exposed to drug during follow-up 3523 11704 5086 3663 5035
Patients with cancer 38 139 54 49 36
Cancers 43 176 67 67 42
Patients with multiple cancers (%) 3 (8) 27 (19) 10 (18) 13 (27) 4 (11)
BCC (%) 38 (88) 150 (85) 57 (85) 59 (88) 34 (81)
SCC (%) 4 (9) 23 (13) 9 (13) 8 (12) 6 (14)
Basosquamous cell carcinoma (%) 0 (0) 1 (1) 0 (0) 0 (0) 1 (2)
Dermatoﬁ  brosarcoma protuberans 0 (0) 1 (1) 1 (1) 0 (0) 0 (0)
Unclassiﬁ  ed skin cancer (%) 1 (2) 1 (1) 0 (0) 0 (0) 1 (2)
First skin cancer reported by (%):
  NHS–IC 36 (95) 121 (87) 49 (91) 38 (78) 34 (94)
  Physician and/or patient 17 (45) 85 (61) 35 (65) 33 (67) 17 (47)
BCC, basal cell carcinoma; nbDMARD, non-biological disease-modifying antirheumatic drug; NF, tumour necrosis factor; NHS–IC, 
National Health Service Information Centre; SCC, squamous cell carcinoma; TNF, tumour necrosis factor.
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case ascertainment by this source, as regional cancer registries 
are allowed up to 18 months to report cancers to the Ofﬁ  ce for 
National Statistics.29 As this source is blind to the treatment 
arm of patients, it is less susceptible to bias, although a general 
surveillance bias among patients treated with anti-TNF thera-
pies cannot be completely excluded.
In this study we also compared the risk of skin cancer between 
individual drugs. There was a suggestion that the incidence of 
BCC was higher for inﬂ   iximab compared with nbDMARD 
than for etanercept or adalimumab, although this ﬁ  nding did 
not reach statistical signiﬁ  cance. A US study found an increased 
risk of skin cancer for inﬂ  iximab (OR 1.7, 95% CI 1.3 to 2.2) 
but not for etanercept (1.2, 95% CI 1.0 to 1.5) or adalimumab 
(0.9, 95% CI 0.5 to 1.8).13 That study was unable to distinguish 
between BCC and SCC, which makes interpretation difﬁ  cult 
given their different pathobiologies. Furthermore, in that study 
cases of malignancy were patient reported and not always his-
tologically conﬁ  rmed.13
In our study, the higher rate for inﬂ  iximab may be partly 
explained by a small number of inﬂ  iximab patients being diag-
nosed with multiple BCC, as the HR for inﬂ  iximab was attenuated 
when the analysis was limited to ﬁ  rst skin cancer. Surveillance 
bias may also explain this ﬁ  nding, as inﬂ  iximab-treated patients 
were assessed every 8 weeks before each inﬂ  iximab infusion: a 
hypothesis further strengthened by the higher rate of physician-
reported events in patients receiving inﬂ  iximab.
An important consideration of this study relates to the SCC 
risk in the anti-TNF cohort. Given that SCC is uncommon in the 
UK, this study may lack power to detect an important increased 
risk following anti-TNF. An indication that this may be case was 
that the HR for anti-TNF was higher when restricted to patients 
aged over 55 years. It is also important to bear in mind that in 
the UK, a history of previous malignancy is listed as a contrain-
dication to anti-TNF. The ﬁ  nding of a 10-fold higher incidence 
of BCC in patients with previous BCC was in keeping with data 
from the general population.30
As with any observational study, it is important to acknowl-
edge the potential for unmeasured confounding. We have col-
lected detailed patient data at baseline for which we have made 
Scotland have not reported an increased risk.6 8 23 An explana-
tion for the increased skin cancer in the BSRBR cohort may be 
that that study comprised individuals with long-standing RA 
with high disease activity at baseline, all of whom have been 
exposed to disease-modifying antirheumatic drugs. The results 
may not be generalisable to patients with mild disease.
Other reasons for differing results may also include variations 
in deﬁ  nitions of skin cancer (with melanoma, SCC, BCC and 
other cancers being variably combined) and different methods 
of case ascertainment. We used English population data from 
2003 to 2008, during which time it has been acknowledged that 
the reporting of skin cancers to the national registry was incom-
plete.26 We only included cancers that were reported to us via 
NHS–IC in this analysis to account for this, meaning any under-
reporting would occur equally and introduce no bias. However, 
we found reporting of ﬁ  rst skin cancers via NHS–IC to be similar 
in both cohorts; nbDMARD only 95% and anti-TNF 87%. In 
comparison, fewer cancers were physician reported, which may 
reﬂ  ect the fact that most skin cancers are diagnosed in primary 
care or dermatology clinics and may not have been recorded in 
rheumatology casenotes.
In patients without reported previous skin cancer we found 
that the addition of anti-TNF did not exacerbate their risk 
of skin cancer when compared with nbDMARD alone with 
follow-up for several years. This is in keeping with a meta-
analysis of randomised controlled trials of anti-TNF in RA.27 
Conversely, another randomised controlled trial meta-analysis 
of anti-TNF across all indications found a twofold increased 
risk of skin cancer.12 In addition, an earlier analysis of BSRBR 
data, published in abstract form,28 reported a possible signal 
for an increased risk of skin cancer. This earlier analysis relied 
more heavily on cancer reporting by the physicians as we only 
allowed a 6-month time lag for NHS–IC reporting. This may 
have increased the effect of reporting bias whereby physicians 
preferentially reported adverse events in patients treated with 
biological agents, perhaps demonstrated by the lower pro-
portion of cases reported by the physician in the nbDMARD 
cohort. The updated analysis presented here allows for up to a 
21-month lag in reporting by the NHS–IC and more complete 
Table 4  Risk of skin cancer for anti-TNF therapy in patients with RA without previous history of skin cancer
 
BCC SCC
nbDMARD Anti-TNF Etanercept Inﬂ  iximab Adalimumab nbDMARD Anti-TNF
Number ever exposed to 
drug during follow-up
3523 11 704 5086 3663 5035 3523 11 704
Exposure time (years) 9342 43 798 19 108 11 700 12 991 9342 43 798
Median exposure time 
per subject (years)
2.65 4.01 3.70 2.70 2.05 2.65 4.01
Patients with cancer 34 121 47 45 29 4 19
Cancers 38 150 57 59 34 4 23
Incident rate/100 000 
patient-years (95% CI)
407 (288 to 558) 342 (290 to 402) 298 (226 to 387) 504 (384 to 650) 262 (181 to 366) 43 (12 to 110) 53 (33 to 79)
Unadjusted HR (95% CI) Ref 0.84 (0.58 to 1.20) 0.71 (0.47 to 1.08) 1.25 (0.83 to 1.89) 0.64 (0.40 to 1.02) Ref 0.93 (0.32 to 2.76)
Age and gender HR (95% CI) Ref 1.20 (0.83 to 1.73) 1.07 (0.70 to 1.63) 1.73 (1.14 to 2.62) 0.89 (0.56 to 1.42) Ref 1.79 (0.59 to 5.41)
aHR (95% CI) Ref 0.95 (0.53 to 1.71) 0.80 (0.44 to 1.47) 1.47 (0.76 to 2.85) 0.73 (0.37 to 1.46) Ref 1.16 (0.35 to 3.84)
First cancer per subject 
incident rate/100 000 
patient-years (95% CI)
364 (252 to 509) 276 (229 to 330) 246 (181 to 328) 376 (273 to 505) 231 (156 to 330)
First cancer per subject 
aHR (95% CI)
Ref 0.81 (0.45 to 1.48) 0.69 (0.37 to 1.29) 1.15 (0.60 to 2.21) 0.68 (0.33 to 1.38)
Excluding ﬁ  rst year of 
follow-up aHR (95% CI)
Ref 1.18 (0.60 to 2.32) 1.05 (0.52 to 2.14) 1.70 (0.81 to 3.58) 0.91 (0.41 to 2.01)
On drug analysis aHR (95% CI) Ref 0.88 (0.48 to 1.60) 0.68 (0.36 to 1.29) 1.24 (0.63 to 2.46) 0.68 (0.32 to 1.42) Ref 0.96 (0.28 to 3.32)
aHR, hazard ratio adjusted for inverse probability of treatment weighting; BCC,basal cell carcinoma; nbDMARD, non-biological disease-modifying antirheumatic drug; RA, rheumatoid 
arthritis; Ref, referent; SCC, squamous cell carcinoma; TNF, tumour necrosis factor.
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adjustments. We lack data on factors such as exposure to ultra-
violet light or skin type.
CONCLUSIONS
Despite the difﬁ  culties in determining valid population rates of 
skin cancer, the ﬁ  ndings from this study add weight to the evi-
dence that skin cancers are increased among treated patients 
with RA, although it cannot support the hypothesis that 
anti-TNF therapy speciﬁ  cally increases this risk of BCC. An 
increased risk of SCC cannot be excluded. Recommendations 
for skin cancer prevention in the general population, such as 
sun avoidance, apply to patients with RA. These data support 
the regular monitoring of patients with RA for unusual or new 
skin lesions.
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